Visudyne verteporfin photodynamic therapy regulatory update

The Appraisal Committee of the U.K.'s National Institute for Clinical Excellence issued a preliminary recommendation that photodynamic therapy for age-related macular degeneration be used only to treat patients with "entirely classic subfoveal choroidal neovascularisation (CNV)." PDT with Visudyne verteporfin from QLTI and NVS is approved in the U.K. to treat AMD patients with predominantly (50% or more) classic CNV. The committee recommended that use of PDT in predominantly classic CNV be restricted to controlled clinical trials. ...